Evidence map›Paper›PMID 34056608›Full record

ArticleNeuro-oncology advances

Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults.

Thiébaud Picart, Marc Barritault, Delphine Poncet, Lise-Prune Berner, Cristina Izquierdo, Emeline Tabouret, Dominique Figarella-Branger, Ahmed Idbaïh, Franck Bielle, Véronique Bourg and 8 more

Open access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Pooled it
  2. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  3. Article
  4. Article
  5. Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. A patient with heterochronous double primary tumor of basal ganglia germ cell tumors followed by diffuse hemispheric glioma: a case report.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Article
  20. An E2 ubiquitin-conjugating enzyme links diubiquitinated H2B to H3K27M oncohistone function.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Thiébaud PicartDepartment of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France.ORCID https://orcid.org/0000-0001-6494-6725
Marc BarritaultCancer Initiation and Tumoral Cell Identity Department, Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France.ORCID https://orcid.org/0000-0003-3311-4058
Delphine PoncetUniversity Claude Bernard Lyon I, Villeurbanne, France.
Lise-Prune BernerDepartment of Neuroradiology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France.ORCID https://orcid.org/0000-0002-9483-0683
Cristina IzquierdoDepartment of Neurooncology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France.
Emeline TabouretDepartment of Neurooncology, AP-HM, Hôpital de la Timone, Marseille, France.ORCID https://orcid.org/0000-0002-4031-2178
Dominique Figarella-BrangerAix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.ORCID https://orcid.org/0000-0002-3604-887X
Ahmed IdbaïhSorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.ORCID https://orcid.org/0000-0001-5290-1204
Franck BielleDepartment of Neuropathology, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France.ORCID https://orcid.org/0000-0001-6564-6388
Véronique BourgDepartment of Neurology, Hôpital Pasteur, Nice, France.
Fanny Burel VandenbosDepartment of Neuropathology, Hôpital Pasteur, Nice, France.ORCID https://orcid.org/0000-0001-8976-0126
Elizabeth Cohen-Jonathan MoyalDepartment of Radiation Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse - Oncopôle, Toulouse, France.ORCID https://orcid.org/0000-0002-6593-9276
Emmanelle Uro-CosteCentre de Recherches contre le Cancer de Toulouse, INSERM U1037, Toulouse, France.ORCID https://orcid.org/0000-0001-7300-5724
Jacques GuyotatDepartment of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France.
Jérôme HonnoratUniversity Claude Bernard Lyon I, Villeurbanne, France.
Mathieu GabutCancer Initiation and Tumoral Cell Identity Department, Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France.ORCID https://orcid.org/0000-0001-7343-5361
David MeyronetCancer Initiation and Tumoral Cell Identity Department, Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France.ORCID https://orcid.org/0000-0001-9943-4578
François DucrayCancer Initiation and Tumoral Cell Identity Department, Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France.
Université Claude Bernard Lyon 1 · FRCentre National de la Recherche Scientifique · FRHospices Civils de Lyon · FRInserm · FRHôpital Pasteur · FRUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiffuse hemispheric gliomas, H3 G34-mutant (DHG H3G34-mutant) constitute a distinct type of aggressive brain tumors. Although initially described in children, they can also affect adults. The aims of this study were to describe the characteristics of DHG H3G34-mutant in adults and to compare them to those of established types of adult WHO grade IV gliomas.

methodsThe characteristics of 17 adult DHG H3G34-mutant, 32 H3.3 K27M-mutant diffuse midline gliomas (DMG), 100 IDH-wildtype, and 36 IDH-mutant glioblastomas were retrospectively analyzed.

resultsMedian age at diagnosis in adult DHG H3G34-mutant was 25 years (range: 19-33). All tumors were hemispheric. For 9 patients (56%), absent or faint contrast enhancement initially suggested another diagnosis than a high-grade glioma, and diffusion-weighted imaging seemed retrospectively more helpful to suspect an aggressive tumor than MR-spectroscopy and perfusion MRI. All cases were IDH-wildtype. Most cases were immunonegative for ATRX (93%) and Olig2 (100%) and exhibited

conclusionsAdult DHG H3G34-mutant are associated with distinct characteristics compared to those of established types of adult WHO grade IV gliomas. This study supports considering these tumors as a new type of WHO grade IV glioma in future classifications.

Indexed as

diffuse hemispheric gliomaH3.3 G34R/V mutationH3.3 K27M mutationPNETsurvival

Identifiers

PMID34056608
PMCPMC8156974
OpenAlexW3153536989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.